@article{35de2f570c7740c49f583482480064d1,
title = "Racial resentment and support for decriminalization of drug possession in the United States",
abstract = "Drug criminalization creates significant barriers to prevention and treatment of substance use disorders and racial equity objectives, and removal of criminal penalties for drug possession is increasingly being endorsed by health and justice advocates. We present empirical data estimating the share of U.S. adults who support eliminating criminal penalties for possession of all illicit drugs, and examine factors associated with public support. Data from the Johns Hopkins COVID-19 Civic Life and Public Health Survey, a probability-based nationally representative sample of 1222 U.S. adults, was collected from November 11–30, 2020. Support for decriminalizing drug possession was assessed overall and by sociodemographic factors and attitudes towards politics and race. Correlates of support were examined using multivariable logistic regression. Thirty-five percent of adults supported eliminating criminal penalties for drug possession in the U.S. In adjusted regression models, respondents who were younger or identified as politically liberal were more likely to support decriminalization relative to other groups, and respondents who were Hispanic or identified strongly with their religious beliefs were less likely to support decriminalization. Among white respondents, greater racial resentment was strongly associated with reduced support for drug decriminalization. Support for drug decriminalization varies considerably by beliefs about politics and race, with racial resentment among white Americans potentially comprising a barrier to drug policy reform. Findings can inform communication and advocacy efforts to promote drug policy reform in the United States.",
keywords = "Decriminalization, Drug policy, Incarceration, Racial resentment, Substance use",
author = "Saba Rouhani and McGinty, {Emma Elizabeth} and Weicker, {Noelle P.} and White, {Rebecca Hamilton} and Lindsay LaSalle and Barry, {Colleen L.} and Sherman, {Susan G.}",
note = "Funding Information: In 2018, the United Nations (UN) Chief Executives board representing 31 UN agencies released a position statement announcing unanimous support for the decriminalization of drug possession for personal use.(Csete et al., 2016; United Nations Chief Executive Board for Coordination, 2018) Calls for decriminalization in the U.S. specifically were amplified in 2020, as high levels of COVID transmission among incarcerated people and a resurgence of national movements against racialized policing increased support for decarceration, especially for non-violent offenses.(Fair and Just Prosecution, 2020) Some jurisdictions suspended prosecutions of drug possession,(Brennan Center for Justice, 2021) while Oregon passed a law(Oregon State Legislature, 2020) decriminalizing possession of all drugs for personal use. Despite the growing interest in decriminalization reforms in the U.S., there is limited empirical data characterizing support for decriminalization of all drugs in this setting. Moreover, there is a parallel political faction which continues to endorse more punitive approaches that criminalize PWUD, evidenced by adoption of stricter punishments for possession and sale of synthetic opioids and prenatal drug use, and racially charged rhetoric in debates about federal funding for harm reduction.(Thomas et al., 2018; Beletsky and Davis, 2017; Stolberg, 2022; Drug Policy Alliance, 2017) Funding Information: Data collection was funded by the Robert Wood Johnson Foundation, the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins University Alliance for a Healthier World's 2020 COVID-19 Launchpad Grant. Dr. Sherman is funded by an endowment from the Bloomberg American Health Initiative. Funders were not involved in study design, data management, analysis, and interpretation, or manuscript preparation and review. No financial disclosures were reported by the authors of this paper. Dr. Sherman serves as an expert witness in opioid litigation. No other authors have conflicts or disclosures. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = oct,
doi = "10.1016/j.ypmed.2022.107189",
language = "English (US)",
volume = "163",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",
}